Phase 4
N=121
Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial
Abortion, Induced · Cervical Preparation · Pain
Bottom Line
View on ClinicalTrials.gov: NCT03080493 ↗Enrolled (actual)
121
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion — 2; 2.5 Numeric rating scale pain score change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Gabapentin 600mg (Drug); Placebo oral capsule (Drug); acetaminophen/codeine and ibuprofen (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of California, Davis
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion |
2; 2.5 | — |
| SECONDARY Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion |
1; 2 | — |
| SECONDARY Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion |
3.5; 4 | — |
| SECONDARY Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion |
3; 3.5 | — |
| SECONDARY Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&E Procedure (Day Following Dilator Insertion) |
0.5; 1 | — |
| SECONDARY Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine) |
35; 40 | — |
Summary
Women having abortion procedures between 15 weeks 0 days and 23 weeks 6 days gestational age on the day of their procedure commonly have dilators placed in their cervix overnight before the abortion procedure. The dilators are put in during a pelvic exam in the clinic and after women go home they expand slowly overnight to open the cervix before the abortion procedure the next day. This can be a painful experience and health care providers often give women different kinds of pain medicine to help them.
The investigators are interested in whether a medicine called gabapentin, which is a non-narcotic medicine, could help. Gabapentin is approved by the U.S. Food and Drug Administration (FDA) for prevention of seizures and for treating nerve pain and doctors are also using it to decrease pain for people having surgical procedures.
The main goals of our study are to learn about:
1. Women's pain experience with dilators in their cervix overnight before the abortion procedure
2. How well gabapentin works to decrease women's pain while they have the dilators in their cervix
Women who enroll in the study will get a dose of either gabapentin or placebo (a pill with no medicine in it) before their dilators are placed in the clinic. The medication they get (gabapentin or placebo) will be chosen by chance, like flipping a coin. Neither the women in the study nor the doctors giving them the medication will know which medication they receive so the investigators can learn about their pain without being influenced by knowing which medication they take. Doctors will be able to find out which medication women got if there is an emergency or if it changes their medical care.
The investigators will communicate with women in real time overnight by text messaging to see how much pain they are having in the moment and how much pain medicine they are taking.
The investigators hypothesize that women who receive gabapentin will have a smaller increase in their pain with the dilators than women who receive placebo (a pill with no medicine in it).
The investigators' findings will help doctors understand women's pain experience with dilators better and possibly provide a new way of treating pain with gabapentin.
Eligibility Criteria
Inclusion Criteria
- 15 weeks 0 days gestational age - 23 weeks 5 days gestational age at time of dilator insertion
- Able to read and write in English
- Active cell phone with text messaging capability
- Ride home from dilator insertion clinic appointment
Exclusion Criteria
- Current use of gabapentin or pregabalin
- Allergy to gabapentin, acetaminophen, codeine, or ibuprofen
- Self reported renal disease (severe impaired renal function)
- Self reported current or chronic narcotic use (typical daily use)
- Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data
Data sourced from ClinicalTrials.gov (NCT03080493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.